Agios Pharmaceuticals AGIO Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's business segments — net loss?
- Agios Pharmaceuticals (AGIO) reported business segments — net loss of -$99.11M in Q1 2026.
- How has Agios Pharmaceuticals's business segments — net loss changed year-over-year?
- Agios Pharmaceuticals's business segments — net loss decreased by 11.0% year-over-year, from -$89.29M to -$99.11M.
- What is the long-term trend for Agios Pharmaceuticals's business segments — net loss?
- Over 2 years (2022 to 2025), Agios Pharmaceuticals's business segments — net loss has grown at a 33.4% compound annual growth rate (CAGR), from -$231.8M to -$412.78M.
- What does business segments — net loss mean?
- This metric represents the net financial result for the reportable segment after accounting for all revenues, gains, and operating expenses. It indicates whether the segment is currently generating a profit or operating at a loss during the reporting period. This is a primary indicator of the segment's financial health and its contribution to the company's overall profitability.